MyFinsight

HomeBlogAboutContact

MyFinsight

Making company financials insightful for everyone

Quick Links

  • About
  • Blog
  • Contact

Follow Us

  • X.com
  • Thread
  • Instagram

© 2026 MyFinsight. All rights reserved.

|||

For the quarter ending 2025-09-30, ENTX had $7,919K increase in cash & cash equivalents over the period. -$5,617K in free cash flow.

Cash Flow Overview

Change in Cash
$7,919K
Free Cash flow
-$5,617K

Unit: Thousand (K) dollars (except for numbers of shares and EPS)
Cash Flow
2025-09-30
Effect of exchange rate changes on cash
29
Net loss
-8,423
Depreciation
23
Share-based compensation
2,040
The amount of finance income (expenses), net
8
Increase in other current assets
219
Decrease (increase) in accounts receivable
-126
Increase (decrease) in accounts payable
84
Increase (decrease) in accrued liabilities and other operating liabilities
840
Net cash provided by (used in) operating activities
-5,537
Purchase of property and equipment
80
Net cash provided by (used in) investing activities
-80
Proceeds from issuance of common stock
6,254
The amount represents proceeds from issuance of shares under collaboration agreement
7,190
Issuance cost
262
Proceeds from warrant exercises
354
Net cash provided by (used in) financing activities
13,536
Cash, cash equivalent, restricted cash, and restricted cash equivalent, period increase (decrease), excluding exchange rate effect, including discontinued operation
7,919
Cash and cash equivalents at beginning of period
8,740
Cash and cash equivalents at end of period
16,688
Unit: Thousand (K) dollars

Time Plot

Show the time plot by selecting a row from the table.

Entera Bio Ltd. (ENTX)

Entera Bio Ltd. (ENTX)